Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/12/2026

1. RKLB
2. SPY
3. ACVA
4. RIOT
5. RPD
6. CRWV
7. FERG
8. NVDA
9. HIMS
10. BBIO

Go back to Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1215.02 -16.92 (1.37%)
Previous Close $1231.94    52 Week High $88.16 
Open $1230.65    52 Week Low $67.88 
Day High $1238.00    P/E 281.25 
Day Low $1209.53    EPS $4.32 
Volume 2,113,569